Breath Analysis in Early Stage Lung Cancer Using Infrared Spectroscopy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

51 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-02-25

Study Completion Date

2023-08-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to sample and analyze volatile organic compounds (VOCs) from lung cancer patients and individuals without lung cancer ("healthy" controls). The breath sample analysis will help investigators describe and identify profiles of VOCs found in the breath of patients with lung cancer when compared to normal breath profiles using infrared spectroscopy. This work will help validate early proof of concept results conducted with prototype technology and later stage NSCLC breath samples, and inform future breath testing analysis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Analysis of Volatile Chemicals in Lung Cancer Screen-Eligible Subjects Using Infrared Spectroscopy

NCT05174468

Lung Cancer

TERMINATED

Using Infrared Spectroscopy to Analyze Volatile Organic Compounds (VOCs) in the Breath of Patients With Lung Cancer

NCT06288646

Lung Cancer Non Small Cell Lung Cancer

TERMINATED

Detecting Lung Cancer Based on Exhaled Breath

NCT04419207

Carcinoma Lung Cancer NSCLC +1 more

COMPLETED

Exhaled Breath Biomarkers in Lung Cancer

NCT01386203

Lung Cancer

UNKNOWN

Breath Analysis to Diagnose Lung Cancer

NCT03250390

Lung Cancer

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Globally, lung cancer accounts for the most cancer deaths in both sexes combined. It is believed to develop slowly through progressive accumulation of genetic mutations, hence the disease allows time for diagnosis and curative surgical treatment. Five year survival rates for non-small-cell lung carcinoma (NSCLC) can range from 57-61% when detected in the early stages of disease. This is compared with a survival rate of approximately 6% once distant metastases are present. However, disease diagnosis typically occurs when it has progressed to an advanced stage when patients present with signs and symptoms. Therefore, technologies capable of asymptomatic disease detection will significantly impact lung cancer specific mortality. Metabolomic profiling of cancer measures compounds produced as a result of cellular activity including volatile organic compounds (VOCs) in exhaled breath. Infrared spectroscopy is a proven technique for breath analysis that can measure chemical concentrations in the parts per trillion range for certain VOCs. When coupled with machine learning techniques, this has the potential to be a novel approach for disease detection using exhaled breath.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer Non Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LC Group

Participants will provide two breath samples by exhaling into the breath sampling apparatus and complete the Medical Questionnaire (medications, lifestyle, demographics, smoking history) and survey (lung health). Information related to LC diagnosis (histologic sub-type, tumor stage) will be collected.

No interventions assigned to this group

Control Group

Participants will provide two breath samples by exhaling into the breath sampling apparatus and complete the Medical Questionnaire (medications, lifestyle, demographics, smoking history) and survey (lung health).

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

LC Group:

* ≥ 18 years;
* Able to give informed consent;
* Eligible for lung cancer screening or lung cancer follow-up testing (biopsy, surgery);
* Clinical evidence of lung cancer (metastatic or primary), inclusive of those receiving non-curative treatment, has not yet been treated or is not currently on treatment;
* No history of or any other active cancer;
* Able to provide a breath sample;

Control Group:

* ≥ 18 years;
* Able to give informed consent;
* Eligible for lung cancer screening or lung cancer follow-up testing (biopsy, surgery);
* No history of lung cancer or any other active cancer and is eligible for lung cancer screening;
* Able to provide a breath sample;